清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Treatment Patterns of Newly Diagnosed Asthma Patients in an Urban Setting in China: A Retrospective Longitudinal Real World Evidence Study

医学 哮喘 药方 回顾性队列研究 病历 儿科 队列 内科学 药理学
作者
Zhizhen Hu,Jianwei Xuan,Haijin Zhao,Hangming Dong,Changhui Yu,Yue Gao,Liran Li,Xiaohan Hu,Cai Shao xi
出处
期刊:Research Square - Research Square 被引量:1
标识
DOI:10.21203/rs.3.rs-207486/v1
摘要

Abstract Background: Asthma is prevalent but largely undiagnosed and undertreated in China. Despite readily available effective therapies, the outcomes still leave much to be desired. There is a scarcity of data describing the treatment patterns of patients with newly diagnosed asthma in real world settings. The main goal of this study was to investigate treatment patterns of newly diagnosed asthma patients with up to 1 year follow-up to gain a better understanding of gaps of optimal asthma management in China. Methods : We conducted a large-scale of retrospective cohort analysis of asthma treatment for newly diagnosed patients using an electronic medical record database (SuValue). Eligible patients were at least 14 years old at the diagnosis from 2001 to March 2019. We categorized anti-asthmatic medication use by its classes and documented their use by the underlying disease severity. To examine the use of controlled medications over follow-ups, we summarized their utilization over consecutive 3-month time windows from the initial diagnosis to the end of follow-up. Results: A total of 26,301 patients from tertiary (25.24%), secondary (71.83%) and primary (2.92%) hospitals were included in the study; 54.01% received one or more controller medications during the study period and 30.4% had 12 months of follow-up visits. Initial prescriptions were inhaled corticosteroid (ICS)-containing controller treatment (13.9%), other controller treatment (31.59%), anti-asthmatic relivers (23.76%), symptomatic medications (14.54%) and no medication (16.2%). Patients mostly discontinued their controller prescriptions within 6 months after the initial diagnosis. Of the 45.98% patients not receiving any controller medication, 70.16% used relivers or symptomatic medications during follow-up visits. In patients who had 12-month follow-up visits, 76.86%, 17.25%, 5.88% were deemed to have mild, moderate, and severe asthma, respectively, during the 1 st 3 months. Percentages of severe and moderate asthma patients were halved by the 2 nd 3-month landmark and remained stable over the remaining follow-up visits. There were significant differences in asthma treatment between tertiary and secondary hospitals. Conclusion: In newly diagnosed asthma patients, controller medications were significantly underused while symptom-relief drugs, on the other hand, appeared to be overused. Poor adherence to current guidelines were common and more noticeable in lower tiered hospitals. These findings call for needs of more aggressive asthma management and more educational efforts in China.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Lucas应助芝麻油采纳,获得10
7秒前
呵呵贺哈完成签到 ,获得积分0
13秒前
隐形曼青应助傲娇的觅翠采纳,获得10
24秒前
gszy1975完成签到,获得积分10
27秒前
37秒前
42秒前
55秒前
Lorain发布了新的文献求助10
1分钟前
Kevin完成签到 ,获得积分10
1分钟前
1分钟前
2分钟前
深情安青应助光亮的安双采纳,获得10
2分钟前
FashionBoy应助傲娇的觅翠采纳,获得10
2分钟前
linglingling完成签到 ,获得积分10
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
芝麻油关注了科研通微信公众号
2分钟前
2分钟前
芝麻油发布了新的文献求助10
3分钟前
3分钟前
3分钟前
生动的沛白完成签到 ,获得积分10
3分钟前
3分钟前
hhuajw应助科研通管家采纳,获得10
3分钟前
3分钟前
整齐百褶裙完成签到 ,获得积分10
4分钟前
4分钟前
5分钟前
超级无敌泰迪战士完成签到 ,获得积分10
5分钟前
6分钟前
量子星尘发布了新的文献求助10
6分钟前
芝麻油完成签到,获得积分10
6分钟前
光亮的安双完成签到 ,获得积分10
6分钟前
6分钟前
cokevvv发布了新的文献求助10
6分钟前
小玉瓜完成签到,获得积分10
6分钟前
慕青应助cokevvv采纳,获得10
7分钟前
hhuajw应助科研通管家采纳,获得10
7分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Polymorphism and polytypism in crystals 1000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
Russian Politics Today: Stability and Fragility (2nd Edition) 500
Death Without End: Korea and the Thanatographics of War 500
Der Gleislage auf der Spur 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6080374
求助须知:如何正确求助?哪些是违规求助? 7911046
关于积分的说明 16361156
捐赠科研通 5216456
什么是DOI,文献DOI怎么找? 2789173
邀请新用户注册赠送积分活动 1772086
关于科研通互助平台的介绍 1648897